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LDL Low density lipoprotein 
mGFR Measured glomerular filtration rate 
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RCT Randomized controlled trial 
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ABSTRACT 
 
Marine n-3 fatty acids (FAs) may exert beneficial effects on inflammation, fibrosis, and 
endothelial function, which could preserve renal graft function. In this randomized controlled 
trial, 132 Norwegian renal transplant recipients received either 2.6 g of marine n-3 FAs or 
olive oil (control) daily for 44 weeks, in addition to standard care. Thirty patients did not 
complete the trial. The primary endpoint was change (Δ) in measured glomerular filtration 
rate (mGFR) during follow-up. We found no significant difference in Δ mGFR between the 
marine n-3 FA group and controls (6.7 vs 3.8 mL/min/1.73 m2, p=0.15). Significant 
beneficial effects from marine n-3 FA supplementation were, however, seen in secondary 
endpoints plasma triglycerides, plasma high-sensitivity C-reactive protein and brachial artery 
flow mediated dilation. In the per-protocol population, also the renal graft indices percent 
interstitial fibrosis and Chronic Allograft Damage Index were significantly lower in the 
marine n-3 FA group. The cumulative incidence of adverse events did not differ between the 
marine n-3 FA group (n=218) and controls (n=240). In conclusion, marine FA 
supplementation did not improve renal function compared with controls, but was safe, 
lowered plasma triglyceride and high-sensitivity C-reactive protein levels and improved 
endothelial function (Clinical.Trials.gov identifier NCT01744067).  
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INTRODUCTION 
During the last decades, improved surgical procedures and tailored immunosuppressive 
regimens have lowered the risk of graft loss during the first few years after renal 
transplantation, while long-term graft survival has remained virtually unchanged (1). Silent 
alloimmune mediated tissue injury and immunosuppressive drug side-effects are major 
contributors to progressive renal graft fibrosis, the key histological correlate for chronic 
allograft nephropathy and a predictor of graft survival (2, 3). Agents that may improve 
endothelial function or possess anti-inflammatory or anti-fibrotic properties would be 
attractive, since they might increase longevity of grafts. Experimental and clinical trials in 
various patient populations report anti-inflammatory effects by the major marine n-3 fatty 
acids (FAs) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), through synthesis 
of less pro-inflammatory compounds compared with those derived from arachidonic acid, 
inhibition of nuclear factor kappa B and synthesis of inflammation resolving mediators 
resolvins and protectins (4-7). Marine n-3 FAs improve FA oxidative phosphorylation, reduce 
triglyceride levels and possibly improve endothelial function (8-11). Marine n-3 FAs has also 
been linked to prevention of alloimmune mediated tissue injury and premature aging in renal 
grafts, production of regulatory T cells and inhibition of the pro-fibrotic transforming growth 
factor beta -1 / Smad signaling pathway (5, 12-15). A recent randomized clinical trial (RCT) 
in myocardial infarction survivors reported less development of myocardial fibrosis in 
patients who received high-dose marine n-3 FA supplements (16).  
We have previously shown that higher plasma phospholipid marine n-3 FA levels were 
associated with better patient and graft survival in a large cohort (n=1990) of Norwegian renal 
transplant recipients (17, 18). In that observational cohort, plasma marine n-3 FA levels were 
inversely associated with plasma creatinine, inflammatory biomarkers and triglycerides, acute 
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rejections beyond the early post-transplant phase and development of interstitial fibrosis (IF) 
during the first year after transplantation (17-21). 
The present study is the largest RCT investigating the effects of marine n-3 FA 
supplementation in renal transplantation performed to date, and the first to include data on 
renal graft histopathological indices and endothelial function. The main objective of this trial 
was to evaluate whether daily supplementation of 2.6 g marine n-3 FAs for 44 weeks, 
compared with controls, would improve renal function beyond standard care in renal 
transplant recipients.  
 
MATERIALS AND METHODS  
Study participants 
Inclusion criteria of the present trials were age ≥ 18 years, a functional graft (estimated 
glomerular filtration rate [eGFR] according to the Chronic Kidney Disease Epidemiology 
Collaboration formula > 30 mL/min/1.73m2 at 6 – 8 weeks post-transplant) and written 
informed consent (22). Exclusion criteria were allergy to fish, other seafoods or the study 
drug, a kidney donor > 75 years old, participation in another clinical trial and foreign 
citizenship (controls beyond the baseline visit at centers outside Norway, including the 
scheduled visit at one year post-transplant). From 298 patients, who received a renal 
transplant at Oslo University Hospital Rikshospitalet between 15th of June 2013 and 15th of 
June 2014, 176 patients were eligible for inclusion and 132 patients were included in the trial 
(Figure 1). All patients gave written informed consent to participate in the trial and a separate 
written consent was given for renal graft biopsy sampling. The study was approved by the 
Regional Committees for Medical and Health Research Ethics in Norway and The Norwegian 
Medicines Agency. The trial was performed in accordance with the Declaration of Helsinki 
(Clinical.Trials.gov identifier NCT01744067, ORENTRA).  
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Study design, randomization and monitoring 
This study was an investigator initiated, single center, randomized, double blind, controlled 
trial. We used marine n-3 FA ethyl ester (460 mg/g EPA and 380 mg/g DHA [Omacor®, 
Pronova Biopharma] given as one capsule of 1 g three times a day ≈ 2.6 g effective dose of 
EPA plus DHA per day) and controls received extra virgin olive oil, 3 capsules of 1 g per day, 
both provided by Pronova Biopharma. Patients were instructed to take study drugs with meals 
to assure emulsification of the study drug for better gastrointestinal FA uptake and to avoid 
possible interference with concomitant medication (23). Most patients were treated according 
to the standard immunosuppressive protocol, including induction with basiliximab, followed 
by maintenance immunosuppression with prednisolone (n=132), mycophenolate (n=131) and 
the calcineurin inhibitor tacrolimus (n=128). One dose of methylprednisolone was given at 
the time of transplantation. Prednisolone dose was started at 20 mg daily (day 0-14) and 
tapered gradually via 15 mg (day 15-28), 10 mg (day 29-60) and 7.5 mg (day 61-180) to 5 mg 
per day from six months post-transplant. Tacrolimus 0.05 mg/kg twice daily was started at the 
time of transplantation, after which tacrolimus trough concentrations were monitored and 
tacrolimus dose adjusted accordingly with target 3 - 7 µg/L. We used mycophenolate mofetil 
750 twice daily or mycophenolate sodium 540 mg twice daily. Prophylactic treatment with 
ganciclovir was given to cytomegalovirus seronegative recipients with seropositive donors 
and all patients received trimethoprim-sulfamethoxazole as prophylactic treatment against 
pneumocystis carinii pneumonia during the first six months after transplantation. Screening 
for polyoma virus and cytomegalovirus viremia was performed every month during the first 
six months post transplantation and thereafter every third month. 
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Patients were randomly allocated to receive either marine n-3 FAs (n=66) or control oil 
(n=66) by computer generated randomization codes (SAS, Cary, NC, US) provided by the 
Monitor. Allocation concealment was ensured by the randomization method, where study 
participants, care givers and investigators were kept blinded until the final monitoring visit at 
25th May 2017, and by using hard capsules of similar shape and color in both study groups. At 
the final visit the electronic case report form and the study data file were locked and 
randomization codes were made available. There were no code breaks before unblinding.  
 
Study visits, endpoints and procedures 
Study duration was 44 weeks. Study measurements were performed at baseline (8 weeks post-
transplant) and at the end of study (one year after transplantation). Data were entered into an 
electronic case report form at the baseline visit, at scheduled telephone interviews during 
follow-up and four weeks after the final visit, at additional visits in case of serious adverse 
events and at the final visit. 
 
The primary endpoint was absolute change during follow-up (Δ) in measured glomerular 
filtration rate (mGFR), which was measured by iohexol clearance. Secondary renal endpoints 
were renal graft histopathological indices Chronic Allograft Damage Index (CADI), percent 
graft inflammation and percent IF. Additional renal endpoints were fractional excretion of 
protein in urine (FEPR) as a measure of proteinuria and plasma high-sensitive C-reactive 
protein levels (hsCRP) as a measure of systemic inflammation. Secondary cardiovascular 
endpoints were flow mediated dilation as a measure of endothelial function and plasma 
triglyceride, high density lipoprotein (HDL), low density lipoprotein (LDL) and total 
cholesterol levels. Additional cardiovascular endpoints were systolic and diastolic blood 
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pressure, pulse wave velocity as a measure of arterial stiffness and plasma fasting glucose 
levels and two hours post-challenge plasma glucose during an oral glucose tolerance test.  
 
Study procedures are described in detail in the supplemental material. In short, blood samples 
were drawn on the morning of the baseline and final visits with the patient in a fasting state. 
Gas chromatography was used to determine individual plasma phospholipid FA (hereafter 
plasma FA) levels, quantified as weight percentage (wt%) of plasma total FAs (24, 25). 
Marine n-3 FA level was defined as the sum of EPA and DHA. Flow mediated dilation was 
measured by high-frequency ultrasonography examination of the brachial artery diameter. The 
ultrasound probe was placed over the brachial artery 5 cm proximal to the antecubital fossa 
and resting measurements were performed after a minimum of 10 minutes relaxation. 
Thereafter, we inflated a sphygmomanometer cuff on the proximal forearm to stop blood flow 
in the brachial artery for 5 minutes. From continuous video sessions, end-diastole 
measurements were performed before, during occlusion and the first two minutes post-
occlusion. Flow mediated dilation was defined as the change in arterial diameter between the 
largest post-occlusion diameter and the resting diameter and was expressed as absolute (mm) 
and percent change. Carotid femoral pulse wave velocity was measured by use of the 
SphygmoCor® apparatus (AtCor Medical, West Ryde, NSW, AUS). Fasting and two hours 
post challenge plasma glucose during an oral glucose tolerance test were performed in 
patients without overt diabetes. Patients were diagnosed with post transplantation diabetes 
mellitus if they met with one of the following criteria: fasting plasma glucose ≥126 mg/dL 
(≥7.0 mmol/L), two hours post-challenge plasma glucose ≥200 mg/dL (≥11.1 mmol/L) or 
random plasma glucose ≥200 mg/dL (≥11.1 mmol/L) in combination with symptoms of 
hyperglycemia. Ultrasonography guided percutaneous renal graft core biopsies with 18 G 
needle were obtained at baseline and at the final visit. Light microscopical evaluation of the 
A
c
c
e
p
te
d
 A
r
ti
c
le
This article is protected by copyright. All rights reserved. 
biopsies was performed by two investigators (F.P.R. and I.A.E.) who were blinded for the 
patient’s identity and clinical data. We performed a semi-quantitative estimation of percent 
graft inflammation and IF in the renal cortex, outside scar tissue (26). CADI was defined as in 
the original definition (27), with one adjustment made for degree of IF, making it count for 
each 10% step (0-9) as opposed to the 0-3 scale used in the original definition.  
 
Sample size  
Power estimation was based on an absolute difference in Δ mGFR of 8.0 mL/min/1.73m2 
between the study groups and a 20% drop-out rate. To ensure adequate statistical power, we 
calculated that 132 patients had to be included in the trial.  
 
Statistical analysis 
Primary and secondary endpoints were analyzed in intention-to-treat (ITT) and per-protocol 
(PP) populations. Kolmogorov-Smirnov test and normality plots were used to assess 
normality. Difference in Δ values for study endpoints between the marine n-3 FA and control 
group was evaluated by Students t-test for normally distributed data and Mann-Whitney U-
test for non-normally distributed data. A similar statistical approach was used for evaluation 
of baseline and end of study endpoint values. We used Fishers exact test to evaluate 
differences in the cumulative incidence of adverse events between the study groups. A two-
sided p-value of < 0.05 was considered statistically significant. We used SPSS® version 24.0 
(IBM, New York, NY, US) and STATA® version 14.0 (Stata Corp, College Station, Texas, 
US) for statistical analyses. 
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RESULTS  
Demographics 
Patient characteristics are presented in Table 1. In general, the groups were well matched, but 
there was a higher prevalence of hypertension in the marine n-3 FA group. Median baseline 
plasma marine n-3 FA level was 6.0 wt% in both study groups (interquartile range 4.7 – 7.3 
wt%). In patients who received marine n-3 FA supplements and completed the trial, we found 
a mean absolute increase in plasma marine n-3 FA levels of 4.0 wt%, while it remained 
unchanged in the control group (Table 2).  
 
Renal function 
Renal function improved during follow-up in both study groups (Table 2). In the marine n-3 
FA group mGFR increased from 56.2 ± 15.3 mL/min/1.73m2 at baseline to 61.2 ± 14.4 
mL/min/1.73m2 at the end of study, while in controls mGFR increased from 54.9 ± 16.8 to 
59.0 ± 17.4 mL/min/1.73m2 during follow-up (Table S1). There was no significant difference 
in Δ mGFR between the marine n-3 FA group and controls (6.7 ± 11.7 vs 3.8 ± 10.3 
mL/min/1.73m2, p=0.15, Figure S1).  
 
Renal graft fibrosis and chronic allograft damage 
In patients who completed the trial, the degree of IF in the renal cortex remained stable in the 
marine n-3 FA group (12.9 ± 11.5% at baseline and 12.5 ± 10.3% at the end of study) while it 
increased in controls (from 12.6 ± 10.2% at baseline to 16.0 ± 13.0% at the end of study). 
Difference between the study groups for Δ percent IF was statistically significant in PP 
analysis (-0.6 ± 9.0 % in the marine n-3 FA group compared with 3.6 ± 11.1 % in controls, 
p=0.04), but not in ITT analysis (Table 2 and Figure S1). Similarly, in PP analysis, CADI 
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score remained stable during follow-up in the marine n-3 FA group, while it increased in 
controls (Table S1) and Δ CADI differed significantly between the groups (Table 2).  
 
Proteinuria and inflammation  
FEPR was reduced during follow-up in both groups and there was no significant difference in 
Δ FEPR between the study groups (Table 2). The degree of graft inflammation was slightly 
higher at the end of study than at baseline for both study groups (Table S1). There was no 
significant difference in Δ percent graft inflammation between the groups (Table 2 and Figure 
S1). Marine n-3 FA supplementation reduced hsCRP from 4.6 ± 10.2 mg/L at baseline to 3.5 
± 4.0 mg/L at the end of study, as opposed to an increase in the control group from 3.2 ± 4.3 
mg/L at baseline to 5.9 ± 8.1 mg/L at the final visit (Table S1). Thus Δ hsCRP differed 
significantly between the study groups (Table 2).  
 
Endothelial function 
Mean baseline post-occlusion brachial artery diameter was 0.2 mm (~5%) larger than the 
corresponding resting value. During follow-up the difference between post-occlusion and 
resting values increased by 0.1 mm (~2%) on average in the marine n-3 FA group, while it 
remained stable in controls. We found a corresponding significant increase in Δ percent flow 
mediated dilation in the marine n-3 FA group compared with controls (2.0 ± 3.8 % vs 0.5 ± 
2.4 %, p=0.02, Figure S1).  
 
Blood lipids and glucose 
Plasma triglyceride levels decreased significantly in the marine n-3 FA group during follow-
up as opposed to controls (-39.8 ± 74.2 vs -7.8 ± 77.2 mg/dL, p=0.02). Marine n-3 FA 
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supplementation had no effect on plasma HDL, LDL or total cholesterol levels, fasting plasma 
glucose or two hours post-challenge plasma glucose (Table 3).  
 
Blood pressure and arterial stiffness  
There was a slight reduction in systolic blood pressure and pulse wave velocity during follow-
up in both study groups, while diastolic blood pressure remained unchanged (Table S2). 
Marine n-3 FA supplementation had no effect on pulse wave velocity or blood pressure 
(Table 3). 
 
Safety and study drug adherence 
A detailed description of adverse events, reasons for withdrawal from the trial and study drug 
adherence are given in the supplemental material. In short, 30 patients (of whom 16 belonged 
to the marine n-3 FA group) did not complete the trial. Two patients were termed screening 
failure by the Monitor and two patients did not meet at the final visit (Figure 1). During 
follow-up, there were 218 adverse events in the marine n-3 FA group compared with 240 
adverse events in the control group (Table 4). Gastrointestinal discomfort was the most 
frequent complaint in both the marine n-3 FA group (26%) and the control group (32%), 
especially early after study drug initiation, and led to patient withdrawal in 17 cases (9 in the 
marine n-3 FA group and 8 in controls). One patient in the marine n-3 FA group died due to 
cancer. Graft failure occurred in one patient in the control group. There were 15 acute 
rejections in 11 patients in the marine n-3 FA group and 16 acute rejections in 14 patients in 
the control group.  
 
There was no significant difference in tacrolimus trough levels at end of study between the 
groups (marine n-3 FA group: 6.19 ± 2.04 µg/L vs controls: 5.86 ± 1.66 µg/L, p=0.33). Also 
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tacrolimus doses were similar between the study groups (mean dose 4.8 ± 2.4 mg in the 
marine n-3 FA group vs 4.6 ± 2.6 mg in controls, p=0.45).  
 
Adherence to study treatment was evaluated by plasma marine n-3 FA levels. In addition, we 
performed a pill count at the final visit. In the PP population, five patients who received 
marine n-3 FA supplements missed ≥ 5% of doses.  
 
Plasma marine n-3 fatty acid levels and study endpoints 
Subgroup and post-hoc analyses were performed in the ITT population and are presented in 
the supplemental material. End of study plasma marine n-3 FA level, assumed to reflect stable 
levels during follow-up, was significantly correlated with Δ percent IF (r = -0.27, Figure S2), 
Δ CADI (r = -0.32), Δ hsCRP (r = -0.21) and Δ triglycerides (r = -0.29), and a borderline 
significant correlation was found with Δ flow mediated dilation (r = 0.21, p=0.05, Figure S2). 
No significant correlation with end of study plasma marine n-3 FA level was shown with Δ 
mGFR (r = 0.10, p=0.36, Figure S2) or other study endpoints, including renal graft 
inflammation (r = -0.11, p=0.31, Figure S2).  
 
Subgroup analysis showed that patients with lower than median baseline plasma marine n-3 
FA level (<6.0 wt%, n=61), had a significant increase in Δ mGFR after marine n-3 FA 
supplementation compared with controls (8.2 ± 12.6 vs 1.6 ± 11.2 mL/min/1.73m2, p=0.04). 
Change in plasma marine n-3 FA level during follow-up was higher in patients with lower 
baseline levels (r = -0.35, p=0.01, Figure S3).  
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Patients with acute or chronic acute rejections at the final visit (n=5) had higher percent graft 
inflammation, but the low number of cases made comparison between the study groups 
unreliable. Excluding these patients from the analysis did not influence results. 
 
DISCUSSION  
The main finding in this study was that no significant improvement in renal function could be 
demonstrated after 44 weeks of marine n-3 FA supplementation compared with controls. 
However, some beneficial findings were seen in secondary endpoints. Plasma triglyceride and 
hsCRP levels were significantly reduced and flow mediated dilation improved during follow-
up in the marine n-3 FA group compared with controls. In the PP population, percent IF and 
CADI remained stable in the marine n-3 FA group, as opposed to an increase in these 
histopathological indices in controls during follow-up.   
 
Previous RCTs investigating the effects of marine n-3 FA supplementation in renal transplant 
recipients were hampered by low sample sizes and short study duration (28, 29). Although 
renal function improved after marine n-3 FA supplementation in some studies, most trials 
reported a non-significant increase in Δ mGFR of 3 – 5 mL/min/1.73m2 (29). Meta-analyses 
of these RCTs (n = 733 – 812 patients included) found no statistically significant effect on 
renal function (28, 29). The mean increase in Δ plasma marine n-3 FA level of 4.0 wt% in the 
marine n-3 FA group approximates the difference between the lower and upper plasma marine 
n-3 FA quartile in a large observational study of Norwegian renal transplant recipients. In that 
study, beneficial associations between plasma marine n-3 FA level and renal function was 
only shown beyond three years post-transplant, suggesting that potential renoprotective 
effects of marine n-3 FAs might prevent decline in renal function in the long run.  
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Most studies in renal transplant recipients report a significant reduction in plasma 
triglycerides after marine n-3 FA supplementation, but no significant effect on plasma total or 
LDL cholesterol levels, blood pressure or proteinuria (28, 29), in line with findings in the 
present study. The triglyceride lowering effect of marine n-3 FAs has been repeatedly shown 
in various patient populations (9). A small increase in HDL cholesterol level was reported in a 
meta-analysis of RCTs (29), but was not shown in the present study.  
 
We found a reduction in plasma hsCRP levels in the marine n-3 FA group compared with 
controls, suggesting an effect on low-grade systemic inflammation. However, we found no 
significant effect of marine n-3 FA supplementation on percent renal graft inflammation. 
Hernandez and colleagues investigated the effects of marine n-3 FA supplementation 
(effective dose of 1.9 g EPA plus DHA / day) on renal graft inflammation during the first 
three months after transplantation (30). In that trial, markers of tumor necrosis factor pathway 
activation in renal graft tissue, obtained by fine needle aspiration, were lower during acute 
rejection episodes in patients who received marine n-3 FA supplements compared with 
controls. However, they found no difference in inflammatory biomarkers between the study 
groups in patients without rejection. 
 
Chronic inflammation is linked to endothelial dysfunction (31). We found an improvement in 
percent flow mediated dilation in patients who received marine n-3 FA supplements, 
consistent with reports in patients with dyslipidemia and metabolic syndrome (8). Flow 
mediated dilation response indicates the availability of endothelial produced nitrogen 
monoxide to induce local vascular smooth muscle relaxation. The availability of local 
nitrogen monoxide in the vascular wall may be reduced when exposed to reactive oxygen 
species. Improved FA oxidative phosphorylation by marine n-3 FAs could reduce formation 
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of reactive oxygen species and preserve mitochondrial function, partly via increased long-
chain FA and carnitine transporter capacity (10), which serves as a possible explanation for 
the observed improvement in endothelial function. Although endothelial dysfunction is linked 
to ischemia reperfusion injury of renal grafts and is associated with reduced patient survival 
after renal transplantation, the clinical relevance a small improvement in percent flow 
mediated dilation in the transplant setting is unclear (8, 32). 
 
Chronic inflammation is also linked to development of fibrosis in native and transplanted 
kidneys (2). In the present study, we found a significant difference in Δ percent IF between 
the marine n-3 FA group and controls in PP analysis, but not in ITT analysis. The discrepant 
results might have been related to outlier values in the ITT analysis from patients who 
withdrew early from the trial due to serious adverse events. Plasma marine n-3 FA levels were 
associated with less increase in percent IF during follow-up, consistent with findings in a 
previous observational study of Norwegian renal transplant recipients (21). Nonetheless, the 
discrepant results in PP and ITT analyses questions the robustness of the finding. Moreover, 
the clinical relevance of a 3% lower percent IF or a 1 point lower of CADI is unclear (27, 33). 
The recent OMEGA-REMODEL trial in myocardial infarction survivors found less IF outside 
infarction scars and better left ventricular function in patients who received daily 3.4 g of 
EPA plus DHA for six months (16), suggesting that marine n-3 FAs possess anti-fibrotic 
properties.  
 
RCTs investigating the effects of marine n-3 FA supplementation are scarce in patients with 
chronic kidney disease (34). Donadio and colleagues performed a study in an American IgA 
nephropathy cohort and found less decline in renal function after supplementation of 3.2 g of 
EPA plus DHA per day for two years compared with controls (35). However, later trials have 
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not reproduced this finding and there is currently not sufficient evidence to recommend 
marine n-3 FA supplementation in glomerulonephritis or chronic kidney disease (34). Patients 
in the present trial had high baseline plasma marine n-3 FA levels, typical of patients on a 
Nordic diet rich in fish and seafood and about five times higher than levels reported from 
American cohorts (17, 36, 37). Patients with low baseline levels (< 6.0 wt%) had a steeper 
increase in plasma marine n-3 FA level after supplementation and a statistically significant 
improvement of mGFR during follow-up compared with controls. These findings suggest that 
patients with low background marine n-3 FA consumption might be more likely to benefit 
more from marine n-3 FA supplementation. Most other RCTs focusing on marine n-3 FAs in 
renal transplant recipients have been performed in the Mediterranean countries or in the 
Netherlands, where consumption of fish and seafoods is also relatively high (28, 29). Thus, 
similar studies performed in regions with a low consumption of marine n-3 FAs are 
warranted. Also explorative studies investigating effects of marine n-3 FA consumption on 
mechanisms involved in development of renal graft fibrosis would be of interest (7, 12, 38, 
39).  
 
The cumulative incidence of adverse events during follow-up did not differ between the 
groups. Gastrointestinal discomfort was experienced by nearly a third of the patients and is 
common in renal transplant recipients receiving mycophenolate and tacrolimus (40). 
Discontinuation of the study drug resolved the problem in about half of these patients. 
Previous RCTs focusing on marine n-3 FA supplementation in renal transplant recipients 
report very limited data on adverse events (28, 29). Marine n-3 FA supplementation did not 
significantly influence tacrolimus trough concentrations. However, dedicated pharmacokinetic 
studies are needed to evaluate marine n-3 FAs interact with immunosuppressive drugs (23). 
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Based on RCTs performed to date, including the present study, there is not sufficient evidence 
to recommend the use of marine n-3 FA supplements in renal transplantation. However, the 
safety of marine n-3 FAs is well documented and clinical trials report beneficial effects on 
renal and cardiovascular risk factors that may converge into improved patient and graft 
survival, as suggested from observational data (17, 18). Thus, larger studies with longer 
duration are needed to investigate whether marine n-3 FAs preserve renal function and 
improve patient and graft survival.  
 
Strengths of this study include a well described cohort, fatty acid analysis performed at 
baseline and end of study, gold standard measurement of renal function, flow mediated 
dilation and pulse wave velocity measurements, renal histopathological indices, measurement 
of several other cardiovascular risk factors and monitoring of adverse events and concomitant 
medication during follow-up. However, this study has also some important limitations. The 
study duration might have been too short for postulated effects on endothelial function and 
graft fibrosis to translate into improved renal function. The subgroup analyses were hampered 
by low sample sizes, increasing the risk of type II errors. Thirty patients did not complete the 
trial (23% drop-out rate). Most adverse events and patient withdrawals occurred during the 
first two months of follow-up. In retrospect, inclusion of patients at 4 - 6 months post-
transplant might have been more appropriate. We used olive oil as the control oil in this study, 
which may not be inert (41). Finally, study participants were mainly Caucasian men, limiting 
generalizability.  
  
In conclusion, this study demonstrated that supplementation with 2.6 g marine FAs / day for 
44 weeks during the first year after renal transplantation was safe, but did not improve renal 
function compared with controls. Marine n-3 FA supplements lowered plasma triglyceride 
A
c
c
e
p
te
d
 A
r
ti
c
le
This article is protected by copyright. All rights reserved. 
and C-reactive protein levels and improved endothelial function. In patients who completed 
the trial on randomized treatment, marine n-3 FA supplementation prevented development of 
graft fibrosis. This finding may not be robust as a significant effect was not found in the ITT 
analysis. Data on long-term renal function and graft survival is necessary to determine the 
clinical relevance of these findings.  
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FIGURE LEGEND 
Figure 1: Study flow-chart 
CONSORT diagram presenting patient screening, enrollment, randomization and reasons for 
withdrawal from the trial. 
Abbreviations: eGFR: Estimated glomerular filtration rate. FA: Fatty acids. w: Weeks after 
renal transplantation. 
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Additional Supporting Information may be found online in the supporting information tab for 
this article.  
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Table 1: Baseline characteristics and plasma phospholipid fatty acid levels 
 
Variables All patients 
Marine n-3 
FA group 
Control 
group p 
Number of patients 132 66 66  
Recipient age, years 53.4 (13.8) 52.8 (13.5) 54.1 (14.2) 0.61 
Recipient gender, Female, % 25.8 28.8 22.7 0.43 
Ethnicity, Caucasian, % 92.4 90.9 93.9 0.71 
Marine n-3 fatty acids, wt% 6.3 (2.1) 6.4 (2.2) 6.3 (2.1) 0.78 
Eicosapentaenoic acid, wt% 1.8 (1.1) 1.8 (1.1) 1.8 (1.1) 0.71 
Docosahexaenoic acid, wt% 4.5 (1.3) 4.6 (1.3) 4.4 (1.3) 0.45 
Alpha linolenic acid, wt% 0.3 (0.1) 0.3 (0.1) 0.3 (0.1) 0.44 
Linoleic acid, wt% 23.9 (2.8) 23.6 (3.0) 24.2 (3.6) 0.22 
Arachidonic acid level, wt% 8.5 (1.7) 8.5 (1.8) 8.5 (1.5) 0.61 
eGFR, mL/min/1.73m2 68.9 (21.5) 70.7 (21.1) 67.1 (21.8) 0.34 
mGFR, mL/min/1.73m2 55.5 (16.0) 56.2 (15.3) 54.9 (16.8) 0.64 
Body mass index, kg/m2 26.0 (3.9) 25.7 (3.8) 26.3 (4.0) 0.44 
b-Hemoglobin, g/L 12.3 (1.5) 12.3 (1.6) 12.3 (1.3) 0.96 
p-Total cholesterol, mg/dL 223.1 (50.2) 226.6 (55.2) 219.7 (44.8) 0.43 
p-Triglycerides, mg/dL 163.4 (93.5) 172.6 (91.4) 154.3 (95.4) 0.26 
Fasting plasma glucose, mg/dL 100.2 (14.4) 102.0 (16.2) 98.2 (11.8) 0.17 
p-Albumin, g/L 42.4 (2.9) 42.1 (2.8) 42.7 (2.9) 0.21 
hsCRP, mg/L 3.9 (7.8) 4.6 (10.2) 3.2 (4.3) 0.30 
FEPR 3 (2 – 6) 3 (2 – 5) 3 (2 – 6) 0.42 
Primary renal disease, % 
Diabetes nephropathy 
Hypertensive nephropathy 
Glomerulonephritis 
 
12.9 
23.5 
30.3 
 
10.6 
22.7 
33.3 
 
15.2 
24.2 
27.3 0.71 
Pre-transplantation disease, % 
Hypertension 
Diabetes mellitus 
Coronary disease 
Cancer 
 
71.2 
16.7 
12.1 
10.6 
 
78.8 
13.6 
12.1 
7.6 
 
63.6 
19.7 
12.1 
13.6 
 
0.05 
0.35 
>0.99 
0.26 
Drugs used at baseline, % 
Statins 
Acetylsalicylic acid 
ACEi or ARB 
Tacrolimus 
 
24.2 
42.4 
9.8 
97.0 
 
22.7 
40.9 
7.6 
97.0 
 
25.8 
43.9 
12.1 
97.0 
 
0.69 
0.73 
0.38 
>0.99 
Systolic blood pressure, mmHg 134 (15) 132 (14) 135 (17) 0.21 
Diastolic blood pressure, mmHg 82 (10) 81 (11) 82 (9) 0.54 
Pulse wave velocity, m/sec 10.2 (3.2) 9.8 (2.6) 10.5 (3.7) 0.16 
Resting brachial artery diameter, mm 3.9 (0.6) 3.9 (0.7) 4.0 (0.6) 0.33 
Maximum post-occlusion brachial 
artery diameter, mm 4.1 (0.6) 4.1 (0.7) 4.2 (0.6) 0.34 
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Flow mediated dilation, % 4.9 (2.3) 4.7 (2.3) 5.0 (2.3) 0.47 
Nr. of antihypertensive drugs, % 
None 
One 
Two  
Three or more 
 
19.7 
29.5 
29.5 
21.2 
 
15.2 
28.8 
30.3 
25.7 
 
24.2 
30.3 
28.8 
16.7 0.12 
Nr. of previous renal transplants, % 
None 
One 
Two or more 
 
86.4 
12.1 
1.6 
 
89.4 
10.6 
0.0 
 
83.3 
13.6 
3.0 0.50 
Dialysis vintage, months 8 (0 – 20) 7 (0 – 19) 9 (0 – 22) 0.18 
Dialysis mode, % 
Hemodialysis 
Peritoneal dialysis 
Preemptive transplantation 
 
45.5 
23.5 
31.0 
 
40.9 
28.8 
29.3 
 
50.0 
18.2 
31.8 0.35 
ABO incompatible transplantation, % 7.6 6.1 9.1 0.51 
Preformed donor specific antibodies, % 9.8 7.6 12.1 0.38 
Living donor, % 24.2 21.2 27.3 0.42 
Cold ischemia time, hours 11.2 (6.1) 10.8 (5.9) 11.4 (6.4) 0.59 
Delayed graft function, % 11.4 9.1 13.6 0.41 
CADI 4 (2 – 5) 4 (3 – 6) 4 (2 – 5) 0.82 
Renal graft inflammation, % 3 (1 – 8) 3 (1 – 10) 4 (1 – 8) 0.84 
Renal graft fibrosis, % 10 (6 – 17) 10 (6 - 16) 10 (5 – 18) 0.83 
Number of HLA mismatches, % 
None or one 
Two or three 
Four or more 
 
15.9 
51.5 
32.6 
 
13.7 
51.5 
34.8 
 
18.2 
51.6 
30.3 0.77 
Daily use of low-dose marine n-3 fatty 
acid supplements (cod liver oil), % 14.4 12.1 16.7 0.46 
Physical exercise, % 
High intensity ≥ twice per week  
High intensity once per week 
Low intensity ≥ twice per week  
Low intensity once per week 
None 
 
38.6 
3.8 
41.7 
8.3 
7.6 
 
37.9 
7.6 
45.5 
4.5 
4.5 
 
39.4 
0.0 
37.9 
12.1 
10.6 0.28 
Smoking habits, % 
Daily smoker 
Non-daily smoker 
Former heavy smoker 
Former light smoker 
Life-long non-smoker 
 
15.2 
2.3 
8.3 
32.6 
41.7 
 
15.2 
3.0 
6.1 
31.8 
43.9 
 
15.2 
1.5 
10.6 
33.3 
39.4 0.85 
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Baseline patient characteristics and plasma phospholipid levels of major n-3 and n-6 
polyunsaturated fatty acids are presented as percentage for categorical data, median 
(interquartile range) or mean value (standard deviation) for continuous variables. Differences 
between groups were evaluated with Chi square for dichotomous categorical data, Mantel-
Haenzel linear trend for other categorical variables, Mann Whitney U-test for dialysis vintage, 
FEPR and renal graft indices and Student t-test for other continuous variables.  
Abbreviations: ACEi: Angiotensin converting enzyme inhibitor. ARB: Angiotensin II 
receptor blocker. CADI: Chronic Allograft Damage Index. eGFR: Estimated glomerular 
filtration rate (CKD-EPI formula). FA: Fatty acid. FEPR: Fractional excretion of protein in 
urine. HLA: Human leukocyte antigen. hsCRP: Plasma high sensitive C-reactive protein. 
mGFR: Measured glomerular filtration rate. wt%: Weight percentage of total plasma 
phospholipid fatty acids. 
 
Table 2: The effects of marine n-3 fatty acid supplementation on change in renal endpoints 
during follow-up 
 Marine n-3 FA 
group 
 
Control group 
 
Variables n Mean ± SD n Mean ± SD p 
Δ EPA + DHA, wt%      
ITT  61 4.0 ± 2.7 65 0.2 ± 2.2 <0.001 
PP  49 4.4 ± 2.3 52 0.1 ± 1.8 <0.001 
Δ mGFR, mL/min/1.73m2      
ITT  58 6.7 ± 11.7 62 3.8 ± 10.3 0.15 
PP  49 6.7 ± 11.6 49 4.3 ± 10.4 0.29 
Δ CADI      
ITT  43 0.2 ± 2.7 47 0.9 ± 3.0 0.18 
PP  37 -0.3 ± 2.4 40 1.0 ± 3.1 0.03 
Δ Renal graft fibrosis, %      
ITT  50 0.7 ± 9.6 53 3.6 ± 11.0 0.18 
PP  42 -0.6 ± 9.0 45 3.6 ± 11.1 0.04 
Δ Renal graft inflammation, %      
ITT  50 0.9 ± 8.6 53 1.8 ± 9.2 0.53 
PP  42 0.4 ± 8.1 45 2.0 ± 8.5 0.47 
Δ hsCRP, mg/L      
ITT  61 -1.2 ± 11.0 65 2.8 ± 7.1 0.02 
PP  50 -1.9 ± 11.6 52 2.3 ± 7.4 0.04 
Δ FEPR      
ITT  61 -1.5 ± 4.6 65 -1.0 ± 3.9 0.18 
PP  50 -1.8 ± 4.0 52 -1.1 ± 4.2 0.34 
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Differences between the marine n-3 fatty acid (FA) group and the control group (olive oil) 
were evaluated by Mann Whitney U-test (renal graft indices and FEPR) and Student t-test 
(other variables) and as appropriate.  
Abbreviations: CADI: Chronic Allograft Damage Index. DHA: Docosahexaenoic acid. EPA: 
Eicosapentaenoic acid. FA: Fatty acid. FEPR: Fractional excretion of protein in urine. hsCRP: 
Plasma high sensitive C-reactive protein. ITT: Intention-to-treat population. mGFR: Measured 
glomerular filtration rate. PP: Per-protocol population. wt%: Weight percentage of total 
plasma phospholipid fatty acids. 
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Table 3: The effects of marine n-3 fatty acid supplementation on change in cardiovascular 
endpoints during follow-up 
 
 Marine n-3 FA 
group 
 
Control group 
 
Variables n Mean ± SD n Mean ± SD p 
Δ p-Triglycerides, mg/dL      
ITT  61 -39.8 ± 74.2 65 -7.8 ± 77.2 0.02 
PP  50 -41.4 ± 68.3 52 -6.7 ± 83.8 0.02 
Δ p-HDL cholesterol, mg/dL      
ITT  61 -0.6 ± 15.9 65 -2.9 ± 19.8 0.46 
PP  50 -0.2 ± 15.9 52 -1.5 ± 20.2 0.71 
Δ p-LDL cholesterol, mg/dL      
ITT  61 -33.9 ± 44.6 65 -30.3 ± 40.7 0.63 
PP  50 -35.3 ± 45.9 52 -33.7 ± 38.8 0.85 
Δ p-Total cholesterol, mg/dL      
ITT  61 -41.5 ± 50.6 65 -35.1 ± 41.8 0.46 
PP  50 -43.0 ± 52.6 52 -37.7 ± 43.6 0.59 
Δ p-Fasting glucose, mg/dL      
ITT  54 3.8 ± 20.3 45 1.2 ± 10.9 0.44 
PP  45 4.9 ± 21.8 36 1.2 ± 10.9 0.35 
Δ p-2hPG, mg/dL      
ITT  52 -8.3 ± 45.6 44 -6.8 ± 33.7 0.86 
PP  43 -6.0 ± 48.6 35 -7.3 ± 31.6 0.89 
Δ Flow mediated dilation, %      
ITT  52 2.0 ± 3.8 54 0.5 ± 2.4 0.02 
PP  41 2.1 ± 4.0 43 0.7 ± 2.4 0.05 
Δ Pulse wave velocity, m/sec      
ITT  58 -0.6 ± 2.1 58 -0.6 ± 2.4 0.99 
PP  47 -0.7 ± 2.2 47 -0.7 ± 2.3 0.92 
Δ Systolic BP, mmHg      
ITT  61 -5.5 ± 14.4 65 -3.9 ± 14.1 0.53 
PP  50 -5.3 ± 15.0 52 -4.3 ± 13.2 0.72 
Δ Diastolic BP, mmHg      
ITT  61 -2.6 ± 9.1 65 -2.7 ± 9.4 0.96 
PP  50 -3.1 ± 9.3 52 -3.8 ± 9.0 0.69 
 
Differences between the marine n-3 fatty acid (FA) group and the control group (olive oil) 
were evaluated by Student t-test. Abbreviations: BP: Blood pressure. HDL: High density 
lipoprotein. ITT: Intention-to-treat population. LDL: Low density lipoprotein. PP: Per-
protocol population. 2hPG: Two hours post-challenge plasma glucose during an oral glucose 
tolerance test. 
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Table 4: Adverse events  
  
Variables Marine n-3 FA Controls p 
Number of patients 66 66  
Number of adverse events 218 240 0.33 
Death 1 0  
Graft failure 0 1  
Acute rejection episode 15 16  
Chronic antibody mediated rejection 1 1  
De novo donor specific antibodies 3 3  
Polyoma virus nephropathy 1 0  
Polyoma virus viremia 5 3  
Cytomegalovirus disease 2 4  
Cytomegalovirus viremia 4 9  
Recurrence of primary renal disease 2 3  
Post transplantation diabetes mellitus 10 7  
Transplant ureter stenosis 1 3  
Coronary artery disease 0 2  
Peripheral artery stenosis 0 2  
Transplant artery stenosis 1 2  
Stroke 0 1  
Atrial fibrillation 2 2  
Aortic or mitral valve disease 2 0  
Deep vein thrombosis 2 1  
Fracture 2 2  
Cancer (solid organ) 2 2  
Cancer (skin) 1 1  
Septicemia 4 4  
Lower respiratory tract infection 8 6  
Urinary tract infection 5 15  
Gastrointestinal discomfort 
(abdominal pain, diarrhea, nausea or 
regurgitation) 17 21 
 
 
Adverse events during 44 weeks of follow-up. Difference between the marine n-3 fatty acid 
(FA) group and the control group was evaluated by Fishers Exact test. In addition, the 
distribution of selected adverse events is given. 
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